BridgeMD
New treatment option for Primary Open Angle Glaucoma (POAG)
Official title A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study
ClinicalTrials.gov ID: NCT07661329
What this study is testing
What is Bimatoprost ophthalmic solution 0.01% YSBP?
Bimatoprost ophthalmic solution 0.01% YSBP is an investigational medicine, being studied as a potential treatment for primary open angle glaucoma (poag).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd. compared to LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of AbbVie INC in subjects with primary open angle glaucoma (POAG) or ocular hypertension.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- people willing and able to provide voluntary informed consent and to follow protocol requirements.
- Male or females aged ≥18 years.
- people with primary open-angle glaucoma (POAG) or ocular hypertension (OH) in both eyes
- people requiring treatment in both the eyes and able to discontinue the use of all ocular hypotensive medication(s) or switch ocular hypotensive...
- Adequate washout period prior to baseline (Day 0) of any ocular hypotensive medications
You likely can't join if
- Female people with positive pregnancy test or lactating or planning a pregnancy.
- Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation or benzalkonium chloride.
- Current or history of severe hepatic or renal impairment.
- Current or history within 3 months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or...
- Current corneal abnormalities that would prevent accurate IOP readings with tonometer.
- Functionally significant visual field loss as determined by perimetry.
See the full eligibility criteria
- people willing and able to provide voluntary informed consent and to follow protocol requirements.
- Male or females aged ≥18 years.
- people with primary open-angle glaucoma (POAG) or ocular hypertension (OH) in both eyes
- people requiring treatment in both the eyes and able to discontinue the use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.
- Adequate washout period prior to baseline (Day 0) of any ocular hypotensive medications
- Baseline (Day 0/hour 0) IOP ≥22 mm Hg and ≤ 34 mm Hg in both eyes, with difference between the IOP in left and right eyes not being more than 5 mm Hg
- people' IOP is likely to be controlled with monotherapy.
- Baseline best corrected visual acuity equivalent to Snellen acuity of 20/100 or better in each eye, using a logarithmic visual acuity chart.
- Women of childbearing potential (defined as women physiologically capable of becoming pregnant unless they are using an effective method of contraception during the study participation) practicing any of the following...
- Oral or parenteral (injection, patch, or implant) hormonal contraception which has been continuously used for at least 1 month prior to first dose of study medication.
- Intrauterine device (IUD) or intrauterine system (IUS)
- Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)
- Male sterilization (at least 6 months prior to screening, should be the sole male partner for that subject)
- Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation
- Total abstinence; partial abstinence is not acceptable
- No history of addiction to any recreational drug or drug dependence or alcohol addiction
- Female people with positive pregnancy test or lactating or planning a pregnancy.
- Contraindication or known hypersensitivity to Bimatoprost, related class of drugs, or any of the excipients of formulation or benzalkonium chloride.
- Current or history of severe hepatic or renal impairment.
- Current or history within 3 months prior to baseline of any other significant ocular disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either eye (Note: stable myopia, strabismus, and...
- Current corneal abnormalities that would prevent accurate IOP readings with tonometer.
- Functionally significant visual field loss as determined by perimetry.
- people with corneal grafts.
- Subject has contraindication to pupil dilation.
- Use at any time prior to baseline of an intraocular corticosteroid implant.
- Use of contact lens within 1 week prior to baseline.
- Use within 21 days prior to baseline of 1) a topical ophthalmic corticosteroid or 2) a topical corticosteroid.
- Use within 21 days prior to baseline of a systemic corticosteroid.
- Use within 6 months prior to baseline of intravitreal or subtenon injection of an ophthalmic corticosteroid.
- Underwent within 3 months prior to baseline any other intraocular surgery (e.g., cataract surgery). Underwent any filtering surgery, or laser surgery for IOP reduction (e.g., laser trabeculoplasty) within 3 months prior...
- people with a history of non-responder to bimatoprost monotherapy.
- Significant ocular surface findings (e.g., hyperemia or irritation, mild or greater) in either eye found on gross macroscopic or slit lamp examination.
- Severe glaucoma with a cup/disk ratio greater than 0.8 (not including physiological cupping in the Investigators' opinion).
- Chronic use of any systemic medication that may affect IOP with less than 2 months stable dosing regimen (i.e., sympathomimetic agents, betaadrenergic blocking agents, alpha-agonists, alpha-adrenergic blocking agents...
- Central Corneal thickness (CCT) \ 620 microns for study eye.
- Known history or presence of any uncontrolled systemic disease
- History of recurrent ocular seasonal allergies within past 2 years prior to screening.
- Any other medical condition or serious intercurrent illness that, in the Investigator's opinion, may make it undesirable for the subject to participate in the study and would limit adherence to the study requirements.
- Participation in any clinical study within 30 days before the first dose of the study drug.
- people with known cases of active Hepatitis B virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) infection.
- people with aphakia or history of herpes simplex keratitis
The study team makes the final eligibility decision.
Where it's taking place
- Beverly Hills, California, United States
- Inglewood, California, United States
- Newport Beach, California, United States
- Petaluma, California, United States
- Boynton Beach, Florida, United States
- Miami Beach, Florida, United States
- Weston, Florida, United States
- Morrow, Georgia, United States
- Roswell, Georgia, United States
- Louisville, Kentucky, United States
- St Louis, Missouri, United States
- Rochester, New York, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beverly Hills, California, United States; Inglewood, California, United States; Newport Beach, California, United States; Petaluma, California, United States; Boynton Beach, Florida, United States; Miami Beach, Florida, United States and 8 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.